Type 1 diabetes - The Lancet

peptide 1 receptor agonists (GLP-1RAs) and oral sodium–glucose cotransporter 2 (SGLT-2) inhibitors are recommended as second-linetherapybecauseoftheirabil-ity to lower glucose without increasing hypoglycemiarisk,weightlosseffect,and associated cardiovascular benefits (1,2). Semaglutide is a human GLP-1 analog currently available as a once ... ................
................